T Mueller1, J Berndt1, F Hanisch1,2. 1. Department of Neurology, Martin-Luther-University Halle-Wittenberg, Ernst-Grube-Str. 40, D-06120 Halle (Saale), Germany. 2. Department of Neurology, Vivantes Humboldt-Klinikum, Am Nordgraben 2, D-13509 Berlin, Germany.
Abstract
BACKGROUND: The obstetric risk associated with myopathy due to MATR3 mutations is unknown. METHODS: Eight women with the MATR3 p.S85C mutation were recruited. Information on pregnancy, outcome, and effect on muscular function was analysed retrospectively using a pregnancy and delivery questionnaire. The data were compared with information from the German perinatal quality survey. RESULTS: All eight women responded. Their muscular symptoms started between the ages of 36 and 56. Sixteen pregnancies and twelve deliveries could be analysed. Two women had a voluntary abortion after their deliveries for other medical reasons. One woman reported a miscarriage in the first trimester. Five women had pregnancies and deliveries without complications. One woman twice had labour weakness requiring forceps delivery. Another patient twice had a preterm dilatation of the cervical os and forceps deliveries. One of her children had foetal distress and was born preterm and with low birth weight. No perinatal childhood death was reported. No women described muscular symptoms before or during their pregnancies. CONCLUSIONS: Pregnancies in matrin 3 myopathy typically occur several years before the onset of myopathy. No increase in the incidence of foetal distress or miscarriage was found. However, late pregnancies (e.g. in the 5th decade) should be regarded as pregnancies at risk.
BACKGROUND: The obstetric risk associated with myopathy due to MATR3 mutations is unknown. METHODS: Eight women with the MATR3p.S85C mutation were recruited. Information on pregnancy, outcome, and effect on muscular function was analysed retrospectively using a pregnancy and delivery questionnaire. The data were compared with information from the German perinatal quality survey. RESULTS: All eight women responded. Their muscular symptoms started between the ages of 36 and 56. Sixteen pregnancies and twelve deliveries could be analysed. Two women had a voluntary abortion after their deliveries for other medical reasons. One woman reported a miscarriage in the first trimester. Five women had pregnancies and deliveries without complications. One woman twice had labour weakness requiring forceps delivery. Another patient twice had a preterm dilatation of the cervical os and forceps deliveries. One of her children had foetal distress and was born preterm and with low birth weight. No perinatal childhood death was reported. No women described muscular symptoms before or during their pregnancies. CONCLUSIONS: Pregnancies in matrin 3myopathy typically occur several years before the onset of myopathy. No increase in the incidence of foetal distress or miscarriage was found. However, late pregnancies (e.g. in the 5th decade) should be regarded as pregnancies at risk.
Dear Sirs,Myopathy due to mutations in MATR3, which encodes the nuclear matrix protein matrin 3, is a newly described rare myopathy with late onset (usually after the fourth decade) and predominantly distal paresis of legs and arms (Welander type), sometimes with the phenotype of a motor neuron disorder [1], [3], [4]. No information is currently available to guide obstetricians and neurologists in counselling women with matrin 3myopathy about becoming pregnant and giving birth. We used a pregnancy and delivery questionnaire to retrospectively collect data about pregnancy and birth outcomes from 8 patients with matrin 3myopathy due to the MATR3p.S85C mutation diagnosed at the Department of Neurology at Martin-Luther-University Halle-Wittenberg, Germany [2]. An informed consent form was signed by all participants. The study was approved by the Local Ethics Committee of the Martin-Luther-University Halle (Saale).Sixteen pregnancies and twelve deliveries could be analysed (Table 1). None of the women had a chronic disorder at the time of their pregnancies. Two women had chosen a voluntary abortion (P1 at age 25, P4 at age 26) for medical reasons (i.e. due to the complications in the previous pregnancies and deliveries). In both cases the voluntary abortion was of the 3rd pregnancy. P2 had a voluntary abortion at age 29 for private reasons (i.e. reasons other than medical ones).
Table 1
Demographic data and data regarding pregnancies and deliveries in 8 woman with MATR3 p.S85C mutation.
Preterm labour, preterm dilatation of the cervical os, forceps delivery, hypoxia of the newborn
No
23
38, M, 3850
Preterm dilatation of the cervical os and cervical cerclage at week 28, forceps delivery
5.
72
42
22
39, F, 3500
No
1st trimester
30
40, F, 4000
No
At 26 years
6.
60
56
19
40, M, 3000
No
No
7.
55
52
21
40, M, 2930
No
No
8.
74
52
20
40, F, 3500
No
No
Demographic data and data regarding pregnancies and deliveries in 8 woman with MATR3p.S85C mutation.The majority of the women became pregnant two or even three decades prior to the occurrence of functionally disabling symptoms which can be attributed to the myopathy. In all but one woman the myopathy-related symptoms occurred in the 5th decade, i.e. at the end of the reproductive age. None of the women reported an abnormal weakness during the pregnancies, but one (P1) reported labour weakness during both her deliveries and some difficulties in the recovery after the delivery. In other words, all women were asymptomatic for myopathy at the time of their pregnancies. However, the effect of late-onset symptoms on pregnancy and delivery could become increasingly relevant because the mean age at first pregnancy in woman in Germany has been rising over the last decades. In 2010 the mean age during the 3rd pregnancy was 32.4 years in 2010 [5]. Limitations of this study include the small number of patients and a possible recall bias. The data are nevertheless important given the paucity of information currently available.
Informed consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 [5]. Informed consent was obtained from all patients for being included in the study.
Disclosure
F.H. received lecturer honoraria and travel fees from Biomarin, Genzyme, and Astellas Inc. J.B. and T.M. declare that they have no conflict of interest.
Authors: Tobias J Müller; Torsten Kraya; Gisela Stoltenburg-Didinger; Frank Hanisch; Malte Kornhuber; Dietrich Stoevesandt; Jan Senderek; Joachim Weis; Petra Baum; Marcus Deschauer; Stephan Zierz Journal: Ann Neurol Date: 2014-09-16 Impact factor: 10.422
Authors: Jan Senderek; Sean M Garvey; Michael Krieger; Velina Guergueltcheva; Andoni Urtizberea; Andreas Roos; Miriam Elbracht; Claudia Stendel; Ivailo Tournev; Violeta Mihailova; Howard Feit; Jeff Tramonte; Peter Hedera; Kristy Crooks; Carsten Bergmann; Sabine Rudnik-Schöneborn; Klaus Zerres; Hanns Lochmüller; Eric Seboun; Joachim Weis; Jacques S Beckmann; Michael A Hauser; Charles E Jackson Journal: Am J Hum Genet Date: 2009-04-02 Impact factor: 11.025
Authors: Janel O Johnson; Erik P Pioro; Ashley Boehringer; Ruth Chia; Gabriella Restagno; Mario Sabatelli; Robert Bowser; Adriano Chiò; Bryan J Traynor; Howard Feit; Alan E Renton; Hannah A Pliner; Yevgeniya Abramzon; Giuseppe Marangi; Brett J Winborn; J Raphael Gibbs; Michael A Nalls; Sarah Morgan; Maryam Shoai; John Hardy; Alan Pittman; Richard W Orrell; Andrea Malaspina; Katie C Sidle; Pietro Fratta; Matthew B Harms; Robert H Baloh; Alan Pestronk; Conrad C Weihl; Ekaterina Rogaeva; Lorne Zinman; Vivian E Drory; Giuseppe Borghero; Gabriele Mora; Andrea Calvo; Jeffrey D Rothstein; Carsten Drepper; Michael Sendtner; Andrew B Singleton; J Paul Taylor; Mark R Cookson Journal: Nat Neurosci Date: 2014-03-30 Impact factor: 24.884